OXFORD, United Kingdom, 3 December 2018 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, was yesterday named in the list of The Sunday Times Fast Track Disruptors to Watch.
Disruptors to Watch identifies ten of the most disruptive private British companies in a cross-section of industries with the finalists judged on factors such as disruptive potential, management and founders, investor credibility and funds raised.
This recognition comes at the end of a strong year for the Company. Not only has Evox continued to develop its unique exosome-based therapy with the goal of creating a new wave of transformative therapeutics but it has also strengthened the underlying business. The Company concluded a £35.5 million Series B financing in September which included investment from Redmile Group, Oxford Sciences Innovation, GV (formerly Google Ventures), Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford University, and a small number of private investors. In April, the company expanded into a new laboratory and office space at the Oxford Science Park, enhancing its research and development capabilities.
Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented: “Being named as one of The Sunday Times Fast Track Disruptors to Watch is yet another testament to the strides that Evox has made over the last few years and the disruptive capabilities of our exosome-based therapies which we firmly believe have the potential to trigger a paradigm shift in the way treatments can be delivered”.
For enquiries, please contact:
Dr Antonin de Fougerolles, Chief Executive Officer Evox Therapeutics Ltd +44 (0) 1865 570210
Brett Pollard/Natalie Garland-Collins - FTI Consulting +44 (0) 203 727 1000
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.